tirzepatide surmount 2 for the Maintenance of Body Weight Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT‐MAINTAIN - Horn - 2025 - Obesity Tirzepatide Matches Dulaglutide in Large

Survodutide is another dual agonist targeting GLP-1 and glucagon receptors (without GIP), currently in Phase 3 trials

GLP-1 Medications Force Food Industry Rethink Few innovations have disrupted consumer behavior as quickly as GLP-1 weight-loss medications

Sometimes the best beauty secret is simply being properly hydrated at the cellular level

Participants who were randomized to tirzepatide instead of placebo from week 36 for a further 52 weeks were found to maintain at least 80% of their weight loss, compared to 16.6% of those who were randomized to the placebo

Freezing is generally not recommended for reconstituted peptides unless specifically stated in the product's guidelines, as freeze-thaw cycles can cause degradation

Sanitary Ware Market Size Global Report, 20222030 (Polaris Market Research, 2022)